Key result
Target-specific oral anticoagulants are evaluated for their potential role in improving the treatment of venous thromboembolism.
Key points are not available for this paper at this time.
May inform future venous thromboembolism trials; Level 5 evidence leaves clinical role open.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Jack Ansell (2012) studied this question. Target-specific oral anticoagulants are evaluated for their potential role in improving the treatment of venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: